Connect Biopharma Files to Sell 6.13M Ordinary Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Connect Biopharma files to sell 6.13M ordinary shares for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTB
Wall Street analysts forecast CNTB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.380
Low
7.00
Averages
8.67
High
10.00
Current: 2.380
Low
7.00
Averages
8.67
High
10.00
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Connect Biopharma Initiates Phase 2 Trial for Rademikibart in Asthma and COPD
- Clinical Trial Advancement: Connect Biopharma announced the initiation of the Phase 2 Seabreeze STAT trial for Rademikibart, aimed at treating asthma and COPD, marking a significant step in the company's exploration of respiratory diseases.
- Independent Monitoring Review: Following a review by the independent data monitoring committee, no safety concerns were reported based on a pre-specified interim analysis of efficacy involving at least 50 patients, providing confidence for the continuation of the trial.
- Drug Mechanism: Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Ra), effectively treating Th2 inflammatory diseases like asthma by blocking the T-helper 2 (Th2) inflammatory pathway, showcasing its potential in related fields.
- Future Data Release Plans: The company plans to release topline data by mid-2026 and will align with the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial, further advancing the drug's path to market.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Connect Biopharma Reports Positive Clinical Data and Funding
- Clinical Trial Results: Connect Biopharma's Phase 1 study showed that a single 300 mg intravenous dose of Rademikibart led to rapid lung function improvements of over 200 mL in many asthma and COPD patients within 15 minutes, indicating the therapy's unique bronchodilator-like effects and potential for future treatments.
- Best-in-Class Efficacy: In the Phase 3 RADIANT-AD study conducted with Simcere, 96.6% of 259 patients with moderate-to-severe atopic dermatitis achieved EASI-75, 87.1% reached IGA 0/1, and 85.3% achieved EASI-90, demonstrating Rademikibart's significant potential for long-term disease control.
- Funding Plan: The company announced a $20.2 million private placement, selling 6,130,000 shares at $3.25 each, expected to close on March 31, 2026, with proceeds aimed at supporting clinical program development and general corporate purposes, ensuring operational funding into the second half of 2027.
- Stock Price Movement: CNTB's stock has traded between $0.51 and $3.82 over the past year, closing at $3.45 on Friday, with a pre-market increase of 13% to $3.88, reflecting strong market response to the company's positive announcements.
See More
Connect Biopharma Reports Positive Phase 1 Results for Rademikibart
- Clinical Trial Results: Connect Biopharma reported positive topline preliminary results from its Phase 1 clinical pharmacology study of intravenous rademikibart, where a 300 mg dose administered via a 2-minute IV push showed significantly faster FEV1 improvement compared to the previously tested 600 mg subcutaneous administration.
- FEV1 Improvement: Clinically important increases in FEV1 of 100 mL to over 400 mL were observed in many asthma and COPD patients as early as 15 minutes post-dosing, demonstrating the rapid efficacy of rademikibart.
- Sustained Effects: Patients receiving rademikibart maintained mean FEV1 improvements of approximately 200 to 400 mL from baseline through Day 29, indicating its potential for long-term efficacy in both asthma and COPD.
- Future Plans: The company expects to report topline data from the ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD by mid-2026 and plans to quickly engage with the FDA to align on a Phase 3 program.
See More
Rademikibart Phase 3 Trial Shows Promising Efficacy and Safety Results
- Clinical Trial Results: Rademikibart achieved near-maximal responses in approximately 90% of patients across all key endpoints in a 52-week Phase 3 trial, highlighting its potential as a best-in-class treatment for moderate-to-severe atopic dermatitis.
- Safety Profile: The drug demonstrated a safety profile comparable to placebo, with no significant difference in conjunctivitis rates during the 16-week double-blind induction phase, indicating good tolerability for long-term use, which may enhance patient adoption.
- Market Potential: Conducted by Simcere Pharmaceutical, the trial enrolled 259 patients in China, showing significant improvements in key metrics such as EASI-75 and EASI-90, suggesting strong market competitiveness for Rademikibart.
- Strategic Partnership: The exclusive licensing agreement with Simcere allows Connect Biopharma to potentially receive milestone payments up to approximately $110 million, reinforcing its strategic positioning in the Greater China market.
See More
Connect Biopharma Secures $20.2 Million in Private Placement
- Funding Scale and Purpose: Connect Biopharma has entered into a securities purchase agreement to sell 6.13 million shares at $3.25 each, anticipating gross proceeds of approximately $20.2 million, which will be utilized for R&D of clinical products and general corporate purposes, thereby enhancing the company's financial stability.
- Cash Flow Outlook: This financing is expected to extend the company's cash runway into the second half of 2027, ensuring sufficient operational funding in the coming years by combining it with existing cash and short-term investments, supporting ongoing R&D in inflammatory disease treatments.
- Investor Participation: The private placement is led by the company's largest investor, Panacea Venture, and includes participation from various new and existing U.S.-based healthcare investors, reflecting market confidence in Connect Biopharma's future growth and solidifying its position in the biopharmaceutical sector.
- Compliance and Registration Statement: The securities sold in this offering are not registered under the Securities Act of 1933, and Connect Biopharma has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring compliance and paving the way for future securities trading.
See More
Connect Biopharma Initiates Phase 2 Trial for Rademikibart in Asthma and COPD
- Clinical Trial Advancement: Connect Biopharma announced the initiation of the Phase 2 Seabreeze STAT trial for Rademikibart, aimed at treating asthma and COPD, marking a significant step in the company's exploration of respiratory diseases.
- Independent Monitoring Review: Following a review by the independent data monitoring committee, no safety concerns were reported based on a pre-specified interim analysis of efficacy involving at least 50 patients, providing confidence for the continuation of the trial.
- Drug Mechanism: Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Ra), effectively treating Th2 inflammatory diseases like asthma by blocking the T-helper 2 (Th2) inflammatory pathway, showcasing its potential in related fields.
- Future Data Release Plans: The company plans to release topline data by mid-2026 and will align with the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial, further advancing the drug's path to market.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Connect Biopharma Reports Positive Clinical Data and Funding
- Clinical Trial Results: Connect Biopharma's Phase 1 study showed that a single 300 mg intravenous dose of Rademikibart led to rapid lung function improvements of over 200 mL in many asthma and COPD patients within 15 minutes, indicating the therapy's unique bronchodilator-like effects and potential for future treatments.
- Best-in-Class Efficacy: In the Phase 3 RADIANT-AD study conducted with Simcere, 96.6% of 259 patients with moderate-to-severe atopic dermatitis achieved EASI-75, 87.1% reached IGA 0/1, and 85.3% achieved EASI-90, demonstrating Rademikibart's significant potential for long-term disease control.
- Funding Plan: The company announced a $20.2 million private placement, selling 6,130,000 shares at $3.25 each, expected to close on March 31, 2026, with proceeds aimed at supporting clinical program development and general corporate purposes, ensuring operational funding into the second half of 2027.
- Stock Price Movement: CNTB's stock has traded between $0.51 and $3.82 over the past year, closing at $3.45 on Friday, with a pre-market increase of 13% to $3.88, reflecting strong market response to the company's positive announcements.
See More
Connect Biopharma Reports Positive Phase 1 Results for Rademikibart
- Clinical Trial Results: Connect Biopharma reported positive topline preliminary results from its Phase 1 clinical pharmacology study of intravenous rademikibart, where a 300 mg dose administered via a 2-minute IV push showed significantly faster FEV1 improvement compared to the previously tested 600 mg subcutaneous administration.
- FEV1 Improvement: Clinically important increases in FEV1 of 100 mL to over 400 mL were observed in many asthma and COPD patients as early as 15 minutes post-dosing, demonstrating the rapid efficacy of rademikibart.
- Sustained Effects: Patients receiving rademikibart maintained mean FEV1 improvements of approximately 200 to 400 mL from baseline through Day 29, indicating its potential for long-term efficacy in both asthma and COPD.
- Future Plans: The company expects to report topline data from the ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD by mid-2026 and plans to quickly engage with the FDA to align on a Phase 3 program.
See More
Rademikibart Phase 3 Trial Shows Promising Efficacy and Safety Results
- Clinical Trial Results: Rademikibart achieved near-maximal responses in approximately 90% of patients across all key endpoints in a 52-week Phase 3 trial, highlighting its potential as a best-in-class treatment for moderate-to-severe atopic dermatitis.
- Safety Profile: The drug demonstrated a safety profile comparable to placebo, with no significant difference in conjunctivitis rates during the 16-week double-blind induction phase, indicating good tolerability for long-term use, which may enhance patient adoption.
- Market Potential: Conducted by Simcere Pharmaceutical, the trial enrolled 259 patients in China, showing significant improvements in key metrics such as EASI-75 and EASI-90, suggesting strong market competitiveness for Rademikibart.
- Strategic Partnership: The exclusive licensing agreement with Simcere allows Connect Biopharma to potentially receive milestone payments up to approximately $110 million, reinforcing its strategic positioning in the Greater China market.
See More
Connect Biopharma Secures $20.2 Million in Private Placement
- Funding Scale and Purpose: Connect Biopharma has entered into a securities purchase agreement to sell 6.13 million shares at $3.25 each, anticipating gross proceeds of approximately $20.2 million, which will be utilized for R&D of clinical products and general corporate purposes, thereby enhancing the company's financial stability.
- Cash Flow Outlook: This financing is expected to extend the company's cash runway into the second half of 2027, ensuring sufficient operational funding in the coming years by combining it with existing cash and short-term investments, supporting ongoing R&D in inflammatory disease treatments.
- Investor Participation: The private placement is led by the company's largest investor, Panacea Venture, and includes participation from various new and existing U.S.-based healthcare investors, reflecting market confidence in Connect Biopharma's future growth and solidifying its position in the biopharmaceutical sector.
- Compliance and Registration Statement: The securities sold in this offering are not registered under the Securities Act of 1933, and Connect Biopharma has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring compliance and paving the way for future securities trading.
See More
